Understanding the shift from NAFLD and NASH to SLD and MetALD

NAFLD: The Nomenclature Consensus Initiative is a multinational collaboration among national hepatology societies, endocrinology societies, and patient advocacy organizations.

In an effort to better reflect the evolving science and reduce stigma, the medical community has introduced new terminology to replace nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH). The revised classification emphasizes the mechanisms of disease rather than patient behaviors.

The Umbrella Term: Steatotic Liver Disease (SLD)

The term steatotic liver disease (SLD) now serves as the overarching label for liver diseases caused by the accumulation of fat in the liver. This category affects at least 30% of adults and encompasses a range of subtypes based on underlying causes.

A Key Subtype: Metabolic Alcohol-Related Liver Disease (MetALD)

Among the reclassified conditions, MetALD (metabolic alcohol-related liver disease) is gaining attention due to rising levels of alcohol consumption. Understanding MetALD is crucial for improving diagnosis, treatment, and prevention.

Five Key Facts About MetALD

1. MASLD Excludes Heavy Alcohol Use

The most prevalent subtype of SLD is metabolic dysfunction-associated steatotic liver disease (MASLD). By definition, MASLD excludes individuals who engage in heavy alcohol consumption. It currently affects 38% of adults, and this figure is expected to rise to over 55% by 2040.

2–5. (Optional placeholders for additional facts if needed)

If you have more points you’d like to add (like diagnostic criteria, risk factors, treatment approaches, or epidemiology), I can help you flesh those out.